Evidence strength for the context described on this page.
PEPTIDE ATLAS / METABOLIC & FAT LOSS / RETATRUTIDE
EvidenceLate-stage humani
RegulatoryInvestigationali
Recorded content review: SEPTEMBER 2026. Not clinical approval.
Corrections & editorial standardsRetatrutide

A triple GIP/GLP-1/glucagon agonist in clinical development—not an approved drug.
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read the evidence limits
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
This peptide does not have an FDA-approved product or dose for the claims described here. Research dosing and vendor protocols are not consumer prescribing guidance.
The five facts to know first.
RECORDED CONTENT REVIEW
SEPTEMBER 2026
Status is product-, formulation- and indication-specific.
Public education does not establish a personal treatment plan.
Plus 0 research searches. A search link is not a cited study or proof of a claim.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗Where present, the date above records an editorial content review, not medical approval or a live check of every claim. Follow the official product label and regulator links for current status. This page does not establish availability through Modern Bio.
How we describe evidence →OVERVIEW
What Retatrutide is.
An investigational peptide being studied for obesity and related metabolic disease. Products sold online as retatrutide are not FDA-approved clinical-trial supplies.
Activates GIP and GLP-1 receptors while also engaging the glucagon receptor, aiming to combine appetite reduction with altered energy expenditure.
FDA states retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. Clinical-trial evidence is not authorization for products sold online.
Read the current FDA GLP-1 safety statement ↗This checks the stated regulatory point only, not every clinical claim in the profile.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- Substantial average weight reduction and improved glycemic control in the peer-reviewed phase 3 TRIUMPH-2 trial
- A broader phase 3 program is testing efficacy, durability and safety across obesity-related conditions
- Long-term benefit-risk outside trials
- Safety of online or compounded products
- An approved dose, product specification or consumer protocol
TRIUMPH-2 randomized 1,152 adults with obesity or overweight and type 2 diabetes to retatrutide or placebo for 80 weeks. Under the treatment-regimen analysis, mean weight reduction reached 18.8% in the highest-dose study arm versus 5.1% with placebo, with a dose-response across the three retatrutide arms. Glycemic control also improved. Gastrointestinal adverse events were most common. The study does not establish long-term outcomes or FDA approval, and it does not authenticate products sold online.
Read the Lancet trial ↗Evidence grade: Late-stage human. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
CLINICAL CONTEXT
The decision is individual.
Research interest does not establish an approved treatment, a safe personal regimen or reliable product quality. Discuss established alternatives with a qualified clinician.
Identify the outcome, formulation and population actually studied.
Review benefits, uncertainty, contraindications and better-studied alternatives.
A treatment decision needs a responsible clinician, monitoring and a review date.
This public guide does not provide a dosing, injection or self-treatment protocol. Bring the source links and the exact product into a licensed clinical consultation.
MONITORING
What should be tracked.
- Only within a registered trial with protocol-defined safety monitoring
SAFETY
Risks, red flags and reasons to avoid it.
- GI adverse effects and heart-rate changes observed in research
- Unknown long-term effects
- Counterfeit, contamination and dosing risks outside trials
- Products marketed for consumer sale
- Self-injection outside a legitimate clinical trial
- Assuming similarity to tirzepatide means interchangeability
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
SOURCES & RESEARCH LINKS
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. Vendor and community dosing protocols are excluded from this public source list. These are supporting reading links, not a completed claim-by-claim citation map. Search links can lead to changing results; their presence does not establish that a particular study supports this profile.
PRODUCTS & TREATMENT ACCESS
There is no product we can responsibly recommend.
Retatrutide remains investigational and is not FDA-approved. FDA states it cannot be used in compounding under federal law. Trial results do not authenticate products offered online.
A peer-reviewed phase 3 result is not market authorization. A research-chemical vendor cannot recreate trial oversight, manufacturing controls or authenticated supply.
Evidence before affiliate revenue.
We do not rank or sell unapproved research peptides. Use the Atlas to discuss safer, evidence-backed alternatives with a qualified clinician.
Explore evidence-backed options →NEXT STEP
Return to metabolic & fat loss peptides.
Explore the category →YOUR NEXT STEP
Ready for a clinician-led plan?
Clinical review determines the appropriate next step. No treatment is guaranteed.
THE CARE PATH
We order your labs
A licensed clinician reviews results and recommends a plan
Rx sent directly to you when appropriate
Care depends on eligibility and clinical judgment. No prescription is guaranteed. This pathway is not a recommendation for the treatment or test discussed in this guide.
Start your lab reviewExplore free educational tools